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Abstract
Background: Early risk stratification applying cardiac biomarkers may prove useful in sudden cardiac arrest patients.
We investigated the prognostic utility of early-on levels of high sensitivity cardiac troponin-T (hs-cTnT), copeptin
and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with out-of-hospital cardiac arrest (OHCA).
Methods: We conducted a prospective observational unicenter study, including patients with OHCA of assumed
cardiac origin from the southwestern part of Norway from 2007 until 2010. Blood samples for later measurements
were drawn during cardiopulmonary resuscitation or at hospital admission.
Results: A total of 114 patients were included, 37 patients with asystole and 77 patients with VF as first recorded
heart rhythm. Forty-four patients (38.6%) survived 30-day follow-up. Neither hs-cTnT (p = 0.49), nor copeptin (p =
0.39) differed between non-survivors and survivors, whereas NT-proBNP was higher in non-survivors (p < 0.001) and
significantly associated with 30-days all-cause mortality in univariate analysis, with a hazard ratio (HR) for patients in
the highest compared to the lowest quartile of 4.6 (95% confidence interval (CI), 2.1–10.1), p < 0.001. This association
was no longer significant in multivariable analysis applying continuous values, [HR 0.96, (95% CI, 0.64–1.43), p = 0.84].
Similar results were obtained by dividing the population by survival at hospital admission, excluding non-return of
spontaneous circulation (ROSC) patients on scene [HR 0.93 (95% CI, 0.50–1.73), P = 0.83]. We also noted that NT-proBNP
was significantly higher in asystole- as compared to VF-patients, p < 0.001.
Conclusions: Early-on levels of hs-cTnT, copeptin and NT-proBNP did not provide independent prognostic information
following OHCA. Prediction was unaffected by excluding on-scene non-ROSC patients in the multivariable analysis.
Trial registration: ClinicalTrials. gov, NCT02886273.
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Background
Out-of-hospital cardiac arrest (OHCA) is a leading
cause of death and represents a major health problem
in western countries. In Europe, the annual incidence
of Emergency Medical Services (EMS) attended
OHCA is estimated to 84 per 100,000 inhabitants [1].
The mortality rate is high, with an overall rate of sur-
vival to hospital discharge of only 10% [1, 2]. Early
and precise risk stratification of cardiac arrest patients
is important to guide further treatment decisions. On-
scene observations [3] and 24-h intensive care follow-
up recordings [4, 5] are currently being used to pre-
dict survival from OHCA.
Heart disease is a major risk factor for sudden cardiac
arrest [6], with coronary artery disease and cardiomyop-
athies as the two most common causes of sudden car-
diac death [6, 7]. Cardiac arrest with global ischemia and
subsequent resuscitation may contribute to myocardial
injury and dysfunction [8, 9]. Cardiac troponin (cTn)
and copeptin are biomarkers used for early diagnosis of
acute myocardial infarction (AMI) [10, 11] and may also
serve as prognostic indicators following an acute coron-
ary syndrome (ACS) [10, 12]. N-terminal pro-B-type
natriuretic peptide (NT-proBNP) is a well-established
diagnostic marker of heart failure [13] and an important
predictor of mortality in patients with heart failure [13]
or ACS [14]. Both NT-proBNP [15, 16] and copeptin
[17, 18] have been found to predict mortality in critically
ill patients admitted to a medical intensive care unit
(ICU).
Although cardiac biomarkers may be useful for
prognostication in OHCA-patients, available data re-
garding the predictive value of high-sensitivity cardiac
troponin-T (hs-cTnT) [9, 19–21], copeptin [21–23]
and NT-proBNP [19, 21, 24, 25] diverge. The incon-
sistency in previously reported results may be related
to heterogeneity in patient population regarding cause
of cardiac arrest and primary heart rhythm, timing of
blood sampling and follow-up time. Previous studies
have also mainly focused on resuscitated patients ad-
mitted to the ICU.
In our study, we included patients with OHCA of as-
sumed cardiac origin. In a previous publication [21], we
have assessed the prognostic utility of hs-cTnT, copeptin
and NT-proBNP in OHCA patients with ventricular fib-
rillation (VF). We also compared ischemic- with non-
ischemic cardiac arrest. The primary aim of the present
study was to evaluate whether these three biomarkers
may serve as independent prognostic indicators in
OHCA patients with shockable- and non-shockable
heart rhythm, adjusting for clinical variables related to
cardiac arrest. As a second aim, this study was per-
formed to improve our understanding of pathophysi-
ology related to OHCA.
Methods
Study subjects and design
From February 2007 until November 2010 we collected
blood samples from patients ≥18 years of age with
OHCA of assumed cardiac origin, defined according to
the Utstein definitions [26], in the southwestern part of
Norway. All patients recruited in this study received
out-of-hospital advanced cardiac life support according
to the 2005 European Resuscitation Council guidelines
with Norwegian modifications [27]. Blood sampling was
performed by the EMS paramedics, 20 ml of blood was
collected into ethylenediamine tetra acetic acid (EDTA)
-tubes, using a venous cannula, during or immediately
after termination of cardiopulmonary resuscitation
(CPR). In patients with return of spontaneous circulation
(ROSC) without a prehospital blood sample, blood was
collected immediately after hospital admission.
We applied clinical information from hospital records
and collected additional information from electrocardio-
grams, echocardiography and coronary angiography, to
confirm an assumed cardiac cause of OHCA and to
categorize patients [21]. OHCA-patients were divided
into two groups according to first recorded heart
rhythm, asystole or VF. VF-patients were further catego-
rized according to an acute ischemic or non-ischemic
mechanism for sudden cardiac arrest, and whether or
not they had previously known heart disease.
Informed consent was collected retrospectively. All
survivors gave written, informed consent. If the patient
did not regain consciousness before death, the next-of-
kin were asked for consent on the patient’s behalf. This
study was approved by the Regional Board of Research
Ethics and the Norwegian Health Authorities, conducted
in accordance with the Helsinki Declaration of 1975, as
revised in 1989, and registered in ClinicalTrials.gov,
identifier: NCT02886273.
Laboratory methods
After collection, blood samples were centrifuged at
2500 rpm for 10 min. Within 24 h if stored at room-
temperature, or within 48 h if stored at + 4 °C. EDTA-
plasma was stored in aliquots at − 70 °C. Measure-
ments of hs-cTnT, copeptin and NT-proBNP were
performed at the Department of Multidisciplinary La-
boratory Medicine and Medical Biochemistry, Aker-
shus University Hospital, applying standardized
methods, as previous reported [21]. Hs-cTnT (accord-
ing to local stability analyses) and NT-proBNP [28]
are found to be stable in EDTA-plasma for up to 3
days stored at room-temperature, and even longer
when stored at + 4 °C. Ex vivo copeptin stability in
EDTA-plasma is shown for at least 7 days at room
temperature and 14 days at + 4 °C [29].
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Statistical methods
Descriptive statistics are presented as medians with
interquartile range (IQR; 25th to 75th percentile) for
continuous data and as numbers and percentages for
categorical data. Differences in baseline characteristics
were assessed by the Kruskal-Wallis Test for continuous
data and Fisher’s exact test for categorical data. Due to a
right-skewed distribution, hs-cTnT, copeptin and NT-
proBNP levels were logarithmically transformed to the
base-e (loge) prior to analysis. Student’s independent
two-sample t-test was used after loge-transformation to
assess between-group differences, comparing biomarker-
levels in non-survivors with survivors, between the asys-
tole- and VF-group, and between patients who died on
scene and those surviving until hospital admission.
Spearman’s rank correlation coefficient was calculated to
identify a possible relation between biomarker levels and
time of blood sampling.
Patients were divided into quartiles (Q1–4) according
to the hs-cTnT, copeptin and NT-proBNP concentra-
tions. The Kaplan-Meier product limits were used for
plotting the times to event and the log-rank test was
used to test for the equality of the survival curves. Cox
regression models, applying both quartiles and continu-
ous loge-transformed values, were fitted for each of the
biomarkers for the analysis of all-cause mortality within
30-days. We employed two different models for the mul-
tivariable analysis, by including age, loge-creatinine, VF
as first recorded heart rhythm, and duration of resuscita-
tion for Model 1, and adding gender, witnessed cardiac
arrest and bystander-initiated CPR for Model 2. Hazard
ratios (HR) with 95% confidence intervals were calcu-
lated for each of the higher quartiles as compared to
quartile 1. For continuous loge-transformed values, we
employed HR and 95% CI per standard deviation (SD)
increase of the biomarkers. Subgroup analyses were per-
formed in survivors at hospital admission and for VF-
patients.
Statistical analysis was performed using the statistical
package SPSS version 25 (IBM Corp. Armonk, NY). All
tests were 2 -sided with a significance level of 5% with-
out multiplicity adjustment.
Results
During the study period, 361 patients suffered cardiac
arrest of assumed cardiac origin, and were eligible for in-
clusion in this study [21]. Out of these, 155 patients
were sampled. Retrospectively, a total of 41 patients had
to be excluded for different reasons (Fig. 1). The final
population of 114 OHCA-patients was further divided
into two groups according to the first recorded heart
rhythm; 37 patients with asystole and 77 patients with
VF. The group of VF-patients was further classified ac-
cording to the presence of an acute ischemic event, by
which 53 patients had signs of an AMI [21], and 10 of
these had previously been diagnosed with heart disease.
Twenty-one patients suffered sudden cardiac arrest
without signs of an AMI [21], of whom 18 had evidence
of prior heart disease, including coronary artery disease
and/or chronic heart failure. Due to lack of clinical in-
formation, three patients could not be classified as hav-
ing an ischemic- or non-ischemic cardiac arrest.
The baseline characteristics of the patients stratified
according to 30-day mortality are presented in Table 1.
Out of 114 patients, 70 (61.4%) died on scene or before
hospital discharge. All patients (38.6%) surviving to
Fig. 1 Flow chart displaying selection and classification of patients with out-of-hospital cardiac arrest recruited between February 2007 and
November 2010
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hospital discharge were still alive at 30-day follow-up.
Compared to 30-day survivors, non-survivors were older,
had increased prevalence of heart failure and diabetes
and worse kidney function. Asystole as first recorded
heart rhythm was more frequent in non-survivors (53%),
they also had worse cardiac arrest conditions with a sig-
nificant lower proportion of witnessed cardiac arrest and
bystander-initiated CPR, and longer duration of
resuscitation.
Blood samples were drawn from 75 patients during re-
suscitation and from 39 patients at hospital admission,
with a median time from cardiac arrest until blood sam-
pling of 31 and 73.5 min, respectively. We found no cor-
relation between biomarker levels and time of blood
sampling, except for hs-cTnT (r = 0.31, p = 0.001). Me-
dian hs-cTnT concentration was 71 (IQR; 26–231) ng/L,
ranging from 6.0 to 8333 ng/L. Hs-cTnT levels did not
differ significantly between survivors and non-survivors
[median 100 IQR: (21–289) ng/L vs. 66 (26–207) ng/L,
p = 0.49]. Kaplan-Meier analysis revealed no significant
association between quartiles of hs-cTnT and all-cause
mortality at 30-days follow-up (log-rank p = 0.57). In
multivariable analysis, there were no significant associa-
tions between hs-cTnT and 30-days all-cause mortality,
neither in the total population, nor for survivors at hos-
pital admission or in VF-patients (Table 2).
Copeptin levels were elevated in all patients [436
(216–825) pmol/L], and did not differ between the two
Table 1 Baseline characteristics and laboratory values of patients suffering out-of-hospital cardiac arrest
Total population (n = 114) Survivors (n = 44) Non-survivors (n = 70) P-value
Age, y 67 (56–78) 61 (51–68) 72 (62–83) < 0.001
Male gender 95 (83) 36 (82) 59 (84) 0.80
Previous history
Angina pectoris 17 (18) 6 (14) 11 (22) 0.42
Myocardial infarction 33 (31) 10 (23) 23 (36) 0.20
Previous PCI 12 (11) 5 (11) 7 (11) 1.00
Previous CABG 12 (11) 2 (5) 10 (16) 0.12
Heart failure 28 (26) 7 (16) 21 (34) 0.046
Hypertension 53 (52) 19 (43) 34 (58) 0.17
Diabetes mellitus 17 (15) 2 (5) 15 (25) 0.007
Hypercholesterolemia 44 (42) 22 (51) 22 (36) 0.16
Smoking 0.81
Current smoker 27 (32) 13 (33) 14 (31)
Ex-smoker 40 (47) 20 (50) 20 (44)
Cardiac arrest conditions
Witnessed cardiac arrest 87 (77) 39 (89) 48 (70) 0.022
Bystander-initiated CPR 93 (82) 40 (91) 53 (76) 0.049
Duration of resuscitation, min 23 (10–38) 9 (5–15) 32.5 (23–45) < 0.001
Initial rhythm < 0.001
VF 77 (68) 44 (100) 33 (47)
Asystole 37 (33) 0 (0) 37 (53)
Baseline blood samples
Creatinine (μmol/L) 102 (87–122) 93 (82–116) 110 (92–125) 0.013
Total cholesterol (mmol/L) 4.2 (3.6–5.3) 4.9 (4.1–6.5) 3.9 (3.4–5.0) 0.002
CRP (mg/L) 2.5 (1.1–9.9) 2.1 (1.2–4.6) 3.9 (1.0–18.0) 0.15
Glucose (mmol/L) 12.6 (8.0–16.9) 12.6 (8.8–14.7) 12.6 (6.6–17.8) 0.94
Copeptin (pmol/L)a 436 (216–825) 388 (195–825) 445 (244–879) 0.39
hs-cTnT (ng/L)b 71 (26–231) 100 (21–289) 66 (26–207) 0.49
NT-proBNP (pmol/L)c 61 (25–234) 30 (12–98) 105 (35–495) < 0.001
Data are presented as median (interquartile range) or numbers (%)
a n = 110 (96%), b n = 111 (97%), c n = 112 (98%)
Abbreviations: CPR cardiopulmonary resuscitation, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, CRP C-reactive protein, hs-cTnT high-
sensitivity cardiac troponin T, NT-proBNP N-terminal pro-B-type natriuretic peptide
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outcomes, p = 0.38. In survival analysis, copeptin quar-
tiles did not separate survivors and non-survivors after
30 days, log-rank test p = 0.67. There were no statistically
significant associations between copeptin levels and all-
cause mortality at 30-days follow-up, neither in univari-
ate analysis, nor in multivariable models (Table 2).
NT-proBNP was the only biomarker demonstrating a
significant difference between non-survivors and
survivors [105 (35–495) pmol/L vs. 30 (12–98) pmol/L,
p < 0.001]. Patients were grouped into quartiles accord-
ing to NT-proBNP levels; Quartile 1 (Q1): < 24 pmol/L,
Q2: 25–60 pmol/L, Q3: 62–218 pmol/L, and Q4: > 250
pmol/L. The median NT-proBNP level in Q4 was 720
(IQR; 371–2506). Q4-patients were significantly older
with increased prevalence of heart failure and reduced
kidney function, and there was a larger proportion with
Table 2 Univariate- and multivariable Cox regression models applying continuous loge-transformed values of hs-cTnT, copeptin and
NT-proBNP
Univariate Multivariable
Model 1 Model 2
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Total population
loge Hs-cTnT 0.99 (0.78–1.29) 0.99 0.87 (0.66–1.15) 0.34 0.90 (0.68–1.19) 0.46
loge Copeptin 1.08 (0.84–1.39) 0.54 0.88 (0.65–1.20) 0.42 0.92 (0.66–1.28) 0.62
loge NT-proBNP 1.86 (1.44–2.41) < 0.001 0.96 (0.64–1.43) 0.84 0.88 (0.57–1.36) 0.57
Patients surviving to hospital admission
loge Hs-cTnT 0.96 (0.67–1.38) 0.83 0.85 (0.58–1.25) 0.41 0.87 (0.61–1.26) 0.48
loge Copeptin 1.40 (0.95–2.06) 0.093 1.20 (0.75–1.93) 0.45 1.07 (0.62–1.83) 0.81
loge NT-proBNP 1.86 (1.24–2.78) 0.003 0.93 (0.50–1.73) 0.83 0.79 (0.41–1.49) 0.46
VF-patients
loge Hs-cTnT 0.85 (0.59–1.24) 0.41 0.78 (0.52–1.17) 0.24 0.85 (0.56–1.28) 0.43
loge Copeptin 1.15 (0.81–1.63) 0.44 1.01 (0.67–1.51) 0.98 0.95 (0.60–1.52) 0.85
loge NT-proBNP 1.67 (1.07–2.60) 0.023 0.84 (0.43–1.64) 0.61 0.51 (0.22–1.19) 0.12
Abbreviations: loge hs-cTnT loge-transformed value of hs-cTnT, loge Copeptin loge-transformed value of copeptin, loge NT-proBNP loge-transformed value of N-
terminal pro B-type natriuretic peptide, VF ventricular fibrillation, HR hazard ratio, 95% CI 95% confidence interval. Model 1; multivariable model adjusting for age,
loge-creatinine, first recorded heart rhythm and duration of resuscitation. Model 2; multivariable model adjusting for age, loge-creatinine, first recorded heart
rhythm, duration of resuscitation, witnessed cardiac arrest and bystander-initiated cardiopulmonary resuscitation
Fig. 2 Survival curves up to 30-days in OHCA-patients stratified by NT-proBNPquartiles
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asystole as first recorded heart rhythm, Supplemental
Table 1. Kaplan-Meier analysis revealed that the upper
NT-proBNP quartile was significantly associated with
all-cause mortality at 30-days (Fig. 2). Assessed as a con-
tinuous variable, this gave a univariate HR of 1.86,
p < 0.001 for the total population, with similar findings
in survivors at hospital admission [HR 1.86, p = 0.003]
and in VF-patients [HR 1.67, p = 0.023]. Adding age,
loge-creatinine value, VF as primary heart rhythm and
duration of resuscitation in a multivariable Cox regres-
sion model (Model 1), resulted in loss of the significant
association between NT-proBNP and outcome, both in
the total population [HR 0.96, p = 0.84] (Fig. 3) and in
the former two subgroups (Table 2). Similar results were
obtained when adding gender, witnessed cardiac arrest
and bystander-initiated CPR in multivariable model 2
(Table 2).
Among the clinical variables, increasing age was asso-
ciated with death in both models (Model 2; p = 0.001).
Witnessed cardiac arrest, VF as first recorded heart
rhythm and duration of resuscitation were also signifi-
cantly associated with outcome (Fig. 3).
NT-proBNP was significantly higher in patients who
died on-scene (non-ROSC patients) compared to survi-
vors at hospital admission [106.2 (46.5–706.2) pmol/L
vs. 46.8 (17.2–164.4), p = 0.003], but there was no signifi-
cant difference in NT-proBNP levels when comparing
on-scene non-ROSC patients with those who died in
hospital (p = 0.17). Hs-cTnT and copeptin did not differ
significantly between on-scene non-ROSC patients and
survivors at hospital admission.
At 30-day follow-up, all patients in the asystole-group
had died, as compared to 43% in the VF-group. Baseline
characteristics of patients with asystole versus VF as first
recorded heart rhythm are presented in Table 3. NT-
proBNP was the only biomarker that differed between
these two groups, with a significantly higher median
value of 250 (42–1305) pmol/L in the asystole group
compared to 51 (18–111) pmol/L in the VF-group,
p < 0.001. This difference is driven by VF-patients pre-
senting with ischemic cardiac arrest (68.8% of the VF-
population), p < 0.001, and was not evident when com-
paring non-ischemic cardiac patients with the asystole
group, p = 0.74. Hs-cTnT and copeptin were elevated in
both asystole- and VF patients, but there was no signifi-
cant difference between the two groups. These findings
are illustrated by applying loge-transformed values of the
biomarkers as shown in Suppl. Fig. 1.
Discussion
We evaluated the prognostic utility of early-on levels of
hs-cTnT, copeptin and NT-proBNP for all-cause mortal-
ity at 30-days follow-up in clinically characterized
Fig. 3 Adjusted hazard ratio and 95% confidence intervals for 30-day all-cause mortality according to selected risk factors from two different
multivariable models. a Model 1, b Model 2. Hazard ratio (squares), 95% confidence interval (lines). Abbreviations: OHCA, out-of-hospital cardiac
arrest; CPR, cardiopulmonary resuscitation; 95% CI, 95% confidence interval
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patients with OHCA of assumed cardiac origin, present-
ing with asystole or VF.
NT-proBNP was found to be significantly related to
death in univariate analysis, whereas hs-cTnT and
copeptin were not associated with outcome. Adjusting
for demographic- and clinical variables, the prognostic
value of NT-proBNP was attenuated and no longer sta-
tistically significant.
These findings are consistent with two previous stud-
ies [24, 25], reporting a similar association between ad-
mission levels of NT-proBNP and outcome in
resuscitated OHCA patients. There are several possible
mechanisms for increased NT-proBNP/BNP secretion
during cardiac arrest and CPR, including hypoxemia
[30], ischemia [31], ischemia-reperfusion induced in-
flammation [32], therapeutic interventions with adminis-
tration of fluids [33] and vasopressors [34], and
mechanical ventilation with supplementary oxygen ad-
ministration [35]. Myhre et al. 2016 [24] demonstrated
an increase in NT-proBNP levels from admission up to
96 h after hospitalization in OHCA-VT/VF patients.
Longer time to ROSC and higher admission levels of hs-
cTnT were found to be associated with high NT-
proBNP concentrations after 24 h in multivariable
Table 3 Baseline characteristics and laboratory values of patients suffering out-of-hospital cardiac arrest, arranged according to first
recorded heart rhythm
Asystole-patients (n = 37) VF-patients (n = 77) P-value
Age, y 75 (66–86) 63 (54–75) < 0.001
Male sex 26 (70) 69 (90) 0.015
Death at 30 days 37 (100) 33 (43) < 0.001
Died on scene 26 (70) 9 (12)
Died in hospital 11 (30) 24 (31)
Cardiac arrest conditions
Witnessed cardiac arrest 26 (70) 61 (80) 0.24
Bystander-initiated CPR 26 (70) 67 (87) 0.040
Duration of resuscitation, min 28.5 (20–35) 15 (6–43) 0.082
Previous history
Angina pectoris 9 (32) 8 (12) 0.037
Myocardial infarction 11 (32) 22 (30) 0.82
Previous PCI 4 (12) 8 (11) 1.00
Previous CABG 5 (15) 7 (10) 0.51
Heart failure 11 (33) 17 (23) 0.34
Hypertension 21 (64) 32 (46) 0.097
Diabetes mellitus 7 (21) 10 (14) 0.40
Hypercholesterolemia 12 (36) 32 (44) 0.53
Smoking 0.56
Current smoker 10 (39) 17 (29)
Ex-smoker 10 (39) 30 (51)
Baseline blood samples
Creatinine (μmol/L) 101 (92–130) 102 (87–121) 0.42
Total cholesterol (mmol/L) 4.1 (3.5–5.0) 4.3 (3.7–5.4) 0.16
CRP (mg/L) 12.0 (2.0–50.0) 1.9 (1.1–4.1) < 0.001
Glucose (mmol/L) 10.7 (3.7–15.7) 13.7 (9.6–17.2) 0.034
Copeptin (pmol/L)a 402 (244–939) 453 (210–765) 0.82
hs-cTnT (ng/L)b 67 (28–226) 73 (26–231) 0.77
NT-proBNP (pmol/L)c 250 (42–1305) 51 (18–111) < 0.001
Data are presented as median (interquartile range) or numbers (%)
a n = 110 (96%), b n = 111 (97%), c n = 112 (98%)
Abbreviations: VF ventricular fibrillation, OHCA out-of-hospital cardiac arrest, CPR cardiopulmonary resuscitation, PCI percutaneous coronary intervention, CABG
coronary artery bypass graft, CRP C-reactive protein, hs-cTnT high-sensitivity cardiac troponin T
NT-proBNP N-terminal pro-B-type natriuretic peptide
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analysis. Furthermore, 24-h NT-proBNP levels provided
additional prognostic information for the prediction of
1-year mortality. These associations may reflect myocar-
dial changes brought about by the cardiac arrest,
whereas earlier on-site levels of NT-proBNP in our study
most likely will reflect the pre-cardiac arrest condition,
as patients in Q4 as compared to lower quartiles were
more prone to heart failure, were older and presented
with worse renal function. Accordingly, NT-proBNP
levels did not differ between on-scene non-ROSC pa-
tients and those who died in hospital. The prognostic
value of comorbidity has previously been claimed to be
of less importance in OHCA patients [36, 37], and this
may explain the lack of prognostic utility for early-on
NT-proBNP in our study. However, early measurements
of NT-proBNP may help to identify OHCA-patients
with clinically silent heart insufficiency or coronary ar-
tery disease, in need of special medical attention.
Demographic- and clinical factors, such as age, wit-
nessed cardiac arrest, bystander-initiated CPR, primary
heart rhythm and time to ROSC, are previously found to
be prognostically important in cardiac arrest [3, 38–42].
Furthermore, plasma concentrations of NT-proBNP are
known to be associated with age and kidney function
[13]. Multivariable analysis, adjusting for these estab-
lished risk-variables, cancelled the significant univariate
association between early-on levels of NT-proBNP and
outcome. However, in accordance with previous obser-
vations [3, 39–42], we also noted that increasing age and
longer duration of CPR was significantly associated with
increased risk of death, while witnessed cardiac arrest
and VF as primary heart rhythm was associated with a
more favourable outcome (Fig. 3).
In contrast to previous reports [3, 39], bystander-
initiated CPR was not found to be an independent
outcome-predictor in our study, probably cancelled by a
larger proportion of VF-patients and a short EMS
response-time between 8 to 15 min in our recruitment
area.
Furthermore, we found that NT-proBNP differenti-
ated between ischemic VF patients and those present-
ing with asystole. This could be explained by a
difference in baseline risk variables, as previously re-
ported [21]. Patients in the asystole group were older
and a higher proportion suffered from prior cardiac
morbidity, including established coronary artery dis-
ease and heart failure. However, no difference in NT-
proBNP was observed when comparing non-ischemic
VF patients with those presenting with asystole. These
groups had similar baseline characteristics and dif-
fered mainly by the presenting arrhythmia, which may
relate to prognosis. Accordingly, all patients in the
asystole group died as compared to 50% in the non-
ischemic VF group.
The two other biomarkers, hs-cTnT and copeptin,
were not related to outcome, neither in univariate, nor
in multivariable analysis. As previously demonstrated
[9], we found that essentially all resuscitated OHCA-
patients had elevated levels of hs-cTnT. Gilje et al. [20]
found that hs-cTnT peaked 24 h after admission follow-
ing OHCA, but only hs-cTnT at 48 and 72 h, respect-
ively, was independently associated with all-cause
mortality. In our study, we analysed only one blood sam-
ple very close to the cardiac arrest, which may not re-
flect the peak values of hs-cTnT, and the prognostic
utility may have been missed. This assumption is sup-
ported by the FINNRESUSCI substudy by Røsjø et.al [9],
where admission levels of hs-cTnT failed to differ be-
tween hospital non-survivors and survivors and did not
yield independent prognostic information at 1-year fol-
low up in OHCA-VF/VT patients.
Copeptin levels were markedly increased in all patients
in our study and did not differ between 30-days non-
survivors and survivors. Admission levels of copeptin
have previously been demonstrated to independently
predict organ dysfunction and death in the ICU follow-
ing OHCA [22]. As a predictor of long-term mortality,
copeptin levels at day 3 were shown to perform better
than copeptin measured at ICU-admission [23]. In our
early-on sample, elevated copeptin may largely reflect
the stress response during cardiac arrest, rather than
outcome related hemodynamic instability following
ROSC. The prognostic utility of copeptin claimed in the
FINNRESUSCI population [22], is based on samples har-
vested up to 6 h after admission and did not include on-
scene non-ROSC patients.
Strengths
Blood was collected very early after OHCA and includes
non-admitted patients without ROSC, a patient category
usually missed out in previous studies. Also, the initial
cardiac rhythm was recorded in all patients. Pre-hospital
data were collected in accordance with the Utstein
guidelines [26], and advanced cardiac life support was
performed by the EMS paramedics according to current
guidelines [27].
Limitations
The small study population is one of the limitations.
Further studies with larger patient populations should be
performed to assess the prognostic value of these three
biomarkers. Inclusion of patients was restricted to the
largest ambulance centres in the area located closest to
the hospital and to the medical support helicopter to en-
sure timely delivery of blood samples, limiting the po-
tential recruitment area. Furthermore, patient
recruitment could only be performed when there was
enough EMS crew present at the OHCA-scene. Samples
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were obtained during resuscitation and not after death
was declared. Unfortunately, there was a selection bias
due to unbalanced blood sampling in the ROSC and
non-ROSC group of patients. A few patients lacked de-
tailed information regarding the OHCA. Our study is
limited to 30-days observations of outcome.
Conclusions
Early-on levels of hs-cTnT, copeptin and NT-proBNP
did not provide prognostic information following
OHCA. Early measurement of NT-proBNP seems to re-
flect the pre-cardiac arrest condition, and may be useful
to identify OHCA-patients with heart insufficiency and
coronary artery disease, also including subjects with clin-
ically silent conditions.
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